Let's get right to it. This week's first email comes from Frank Z., who writes:"What about SuperGen The pipeline looks promising, stock perking up, positive outcome with their
Next up is Paul S., who asks, "What is your current opinion on Myriad Genetics ( MYGN - Get Report)? Its phase III Alzheimer's trial of Flurizan should have ended March 31, and the ongoing phase II trials of its brain cancer therapy should be completed later this year. The stock seems stuck dead in the water, and the company has been silent recently." Paul is correct, the results from the phase III Flurizan study in mild Alzheimer's patients are expected soon, likely the June-July time frame. The company has already said that the data will be presented at the International Conference on Alzheimer's Disease, which kicks off July 26 in Chicago.
Dave D. writes to opine on ImClone Systems ( IMCL) and its Erbitux, a company and drug I featured in last week's Mailbag: "Hi, Adam -- good article on ImClone, but you missed a few things: 1. Tolerability of Erbitux is not superior to Avastin; most oncology offices keep a crash cart ready when giving Erbitux due to the possibility of life-threatening reactions during the infusion; 2. Avastin data in brain metastasis from non-small cell lung cancer has not yet been presented and could be positive; 3. In colon cancer, EGFR inhibitors
Mike is ticked about the FDA's delay in making an approval decision on Cardiome's ( CRME) heart arrhythmia drug Kynapid. "This is getting absolutely ridiculous! Approaching 120 days post-PDUFA and not a single comment from the FDA, Cardiome or Astellas? This could be the biggest investment debacle I have ever been involved in. Does anyone have accountability anymore?" Mike, I share your frustration. And calling Astellas or Cardiome these days to ask about the situation gets you nowhere. I'm at a loss to explain any of it.
Lastly, William H. goes where few investors these days dare to tread: "What is your take on La Jolla Pharmaceuticals ( LJPC - Get Report). They have a drug for lupus and have announced great results from an interim analysis of a phase III that won't end until 2010." Bill, lupus is the disease where good drugs go to die. Did you see what lupus did to Genentech and Biogen Idec's ( BIIB - Get Report) Rituxan this week? Eek! La Jolla's drug is called Riquent. It failed a phase III program and an FDA submission once before, so this is a do-over of sorts. I have a hard time believing the second shot will be any more successful than the first. La Jolla's stock price (under $2) is telling you the same thing.